New Epilepsy Treatments Offer Hope for Hard-to-Control Seizures

What was studied

This article is a conference summary, not a single clinical trial. It reviewed seizure outcome data reported for 13 investigational epilepsy treatments presented at the 2026 Eilat Conference on New Antiepileptic Drugs and Devices.

The treatments included medicines, gene-based therapies, and a device being developed for several epilepsy types, including developmental and epileptic encephalopathies, Dravet syndrome, SCN2A- and SCN8A-related epilepsies, absence seizures, drug-resistant epilepsy, and acute seizure rescue treatment. The abstract does not give the number of patients in each study or detailed study designs.

What they found

The summary says that at least preliminary seizure outcome data in patients with epilepsy were reported for all 13 investigational treatments, and the authors conclude that the overall evidence justifies expectations for improved health outcomes for children and adults with epilepsy who do not fully benefit from existing therapies. The treatments target different seizure-related pathways, and some are aimed at specific genetic epilepsies.

However, the abstract does not provide exact seizure reduction numbers, side effect rates, or direct comparisons between treatments, so it does not show that any one treatment is proven to work.

Limits of the evidence

This is a narrative conference report, so it cannot establish that these treatments are effective or safe in routine care. Conference data may be preliminary and may change after full publication and larger trials.

The abstract does not report how many people were studied, how long they were followed, how strong the benefits were, or what harms occurred. Because several of these treatments are being investigated for specific genetic or rare epilepsies, findings may be most relevant to selected patient groups.

For families and caregivers

For families, this report suggests that epilepsy research is active and includes more targeted treatments, especially for rare genetic epilepsies and hard-to-treat seizures. It may be encouraging that researchers are studying several different strategies, including rescue treatments, targeted medicines, and gene-based therapies.

Still, this summary is not enough to show which options will truly help, who will benefit most, or when these treatments might become available. Families may want to see whether a treatment is being studied for a specific epilepsy syndrome or gene change.

What to watch next

Stronger evidence will come from larger, peer-reviewed studies that clearly report seizure outcomes, side effects, and which patient groups may benefit most.

Terms in this summary

developmental and epileptic encephalopathies

A group of severe epilepsies in which seizures and abnormal brain activity can affect development and learning.

drug-resistant epilepsy

Epilepsy in which seizures continue despite trying standard anti-seizure medicines.

gene therapy

A treatment designed to change how a gene works or to help the body make a needed protein.

antisense oligonucleotide

A lab-made genetic treatment that aims to change how a cell uses genetic instructions.

focal epilepsy

Seizures that start in one area of the brain.

Dravet syndrome

A rare, severe epilepsy that usually begins in infancy and is often linked to changes in the SCN1A gene.

absence seizures

Brief seizures that can look like staring spells or short lapses in awareness.

rescue therapy

A fast-acting treatment used to stop a seizure or cluster of seizures once it starts.